DK1749097T3 - Replikationskompetente vira, der er i stand til silencing af ekspression af virushæmmende faktor - Google Patents

Replikationskompetente vira, der er i stand til silencing af ekspression af virushæmmende faktor

Info

Publication number
DK1749097T3
DK1749097T3 DK05732404.8T DK05732404T DK1749097T3 DK 1749097 T3 DK1749097 T3 DK 1749097T3 DK 05732404 T DK05732404 T DK 05732404T DK 1749097 T3 DK1749097 T3 DK 1749097T3
Authority
DK
Denmark
Prior art keywords
replication competent
inhibitory factor
target cells
factor expression
virus inhibitory
Prior art date
Application number
DK05732404.8T
Other languages
English (en)
Inventor
Jan Eduard Carette
Beusechem Victor Willem Van
Original Assignee
Vereniging Voor Christelijk Hoger Onderwijs Wetenschappelijk Onderzoek En Patientenzorg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vereniging Voor Christelijk Hoger Onderwijs Wetenschappelijk Onderzoek En Patientenzorg filed Critical Vereniging Voor Christelijk Hoger Onderwijs Wetenschappelijk Onderzoek En Patientenzorg
Application granted granted Critical
Publication of DK1749097T3 publication Critical patent/DK1749097T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
    • C12N2830/205—Vector systems having a special element relevant for transcription transcription of more than one cistron bidirectional
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK05732404.8T 2004-04-15 2005-04-15 Replikationskompetente vira, der er i stand til silencing af ekspression af virushæmmende faktor DK1749097T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04076154A EP1586654A1 (en) 2004-04-15 2004-04-15 Replication competent viruses capable of silencing virus inhibitory factor expression
PCT/EP2005/004152 WO2005100576A2 (en) 2004-04-15 2005-04-15 Replication competent viruses capable of silencing virus inhibitory factor expression

Publications (1)

Publication Number Publication Date
DK1749097T3 true DK1749097T3 (da) 2012-01-30

Family

ID=34928159

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05732404.8T DK1749097T3 (da) 2004-04-15 2005-04-15 Replikationskompetente vira, der er i stand til silencing af ekspression af virushæmmende faktor

Country Status (11)

Country Link
US (1) US8318149B2 (da)
EP (2) EP1586654A1 (da)
JP (1) JP5008552B2 (da)
CN (1) CN1984996B (da)
AT (1) ATE527356T1 (da)
AU (1) AU2005233302B2 (da)
CA (1) CA2562830A1 (da)
DK (1) DK1749097T3 (da)
ES (1) ES2375061T3 (da)
NZ (1) NZ550855A (da)
WO (1) WO2005100576A2 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1586654A1 (en) 2004-04-15 2005-10-19 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Replication competent viruses capable of silencing virus inhibitory factor expression
US20110206639A1 (en) * 2004-04-15 2011-08-25 Christie Vermeulen Replication competent viruses capable of silencing virus inhibitory factor expression
DK1996238T3 (da) 2006-02-28 2016-08-01 Vaxart Inc Kimæriske adenovirale vektorer og DsRNA som TLR3-agonist
RU2010122899A (ru) 2007-11-07 2011-12-20 Е.И. Дюпон Де Немур Энд Компани (Us) Растения, имеющие измененные агрономические характеристики в условиях ограничения азота, и родственные конструкты и способы вовлечения генов, кодирующих полипептиды lnt2 и их гомологи
JP5630769B2 (ja) * 2008-04-11 2014-11-26 井戸川 雅史 アポトーシス誘導剤
EP2320913A4 (en) * 2008-08-09 2012-10-03 Univ Iowa Res Found NUKLEINSÄUREAPTAMERE
WO2010045659A1 (en) * 2008-10-17 2010-04-22 American Gene Technologies International Inc. Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
WO2012047109A2 (en) 2010-10-08 2012-04-12 Orca Therapeutics B.V. Mirna and mirna inhibitors that modulate adenovirus replication and/or adenovirus induced cell death
WO2017070113A1 (en) * 2015-10-19 2017-04-27 The United States of America, as represented by the Secretary, Department of Health and Human Sevices Pharmaceutical composition comprising nanog shrna, and method of using nanog shrna to treat cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613750B2 (en) * 1998-03-19 2003-09-02 Albert Einstein College Of Medicine Of Yeshiva University Method of inhibiting cell proliferation using an anti-oncogene protein
US20020173026A1 (en) * 2001-03-15 2002-11-21 Myriad Genetics, Incorporated Survivin-interacting proteins and use thereof
US6509162B1 (en) * 2000-02-29 2003-01-21 Yale University Methods for selectively modulating survivin apoptosis pathways
US20030084471A1 (en) * 2000-03-16 2003-05-01 David Beach Methods and compositions for RNA interference
US7655787B2 (en) * 2000-08-23 2010-02-02 Purdue Research Foundation pRNA chimera
US20030203372A1 (en) * 2000-12-08 2003-10-30 Ward Neil Raymond Analysis method
US20030138405A1 (en) * 2001-04-17 2003-07-24 Juan Fueyo Conditionally replicative adenovirus to target the Rb and Rb-related pathways
EP1575976A4 (en) * 2001-11-02 2006-08-23 Insert Therapeutics Inc METHODS AND COMPOSITIONS FOR THE THERAPEUTIC USE OF RNA INTERFERENCE
EP1327688A1 (en) * 2002-01-14 2003-07-16 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Adenoviruses with enhanced lytic potency
WO2003062400A2 (en) * 2002-01-24 2003-07-31 The Scripps Research Institute Fiber shaft modifications for efficient targeting
CA2479759A1 (en) * 2002-03-22 2003-10-09 Board Of Regents, The University Of Texas System Protamine-adenoviral vector complexes and methods of use
CA2480308C (en) * 2002-03-27 2011-10-04 Aegera Therapeutics Inc. Antisense iap nucleobase oligomers and uses thereof
US20040023390A1 (en) * 2002-08-05 2004-02-05 Davidson Beverly L. SiRNA-mediated gene silencing with viral vectors
EP1439227A1 (en) * 2003-01-15 2004-07-21 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts HPV-E6-specific siRNAs for the treatment of HPV-related tumors
CA2532534A1 (en) * 2003-07-14 2005-01-20 Japan Science And Technology Agency Methods for diagnosing endometriosis-related diseases
EP1586654A1 (en) 2004-04-15 2005-10-19 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Replication competent viruses capable of silencing virus inhibitory factor expression

Also Published As

Publication number Publication date
CA2562830A1 (en) 2005-10-27
ES2375061T3 (es) 2012-02-24
CN1984996A (zh) 2007-06-20
AU2005233302B2 (en) 2010-07-15
WO2005100576A3 (en) 2006-04-13
AU2005233302A1 (en) 2005-10-27
CN1984996B (zh) 2012-09-05
WO2005100576A2 (en) 2005-10-27
US8318149B2 (en) 2012-11-27
EP1749097A2 (en) 2007-02-07
US20070122385A1 (en) 2007-05-31
EP1586654A1 (en) 2005-10-19
JP5008552B2 (ja) 2012-08-22
JP2007532122A (ja) 2007-11-15
ATE527356T1 (de) 2011-10-15
EP1749097B1 (en) 2011-10-05
NZ550855A (en) 2010-03-26

Similar Documents

Publication Publication Date Title
Martinez-Salas et al. Insights into structural and mechanistic features of viral IRES elements
Sweeney et al. A distinct class of internal ribosomal entry site in members of the Kobuvirus and proposed Salivirus and Paraturdivirus genera of the Picornaviridae
Shimakami et al. Base pairing between hepatitis C virus RNA and microRNA 122 3′ of its seed sequence is essential for genome stabilization and production of infectious virus
Lau et al. Complete genome analysis of three novel picornaviruses from diverse bat species
WO2009039248A8 (en) Methods of treating a flaviviridae family viral infection and compositions for treating a flaviviridae family viral infection
WO2010107739A3 (en) Methods and compositions of treating a flaviviridae family viral infection
BR0016145A (pt) Clones infecciosos
WO2008028661A3 (en) Potexvirus- derived replicon
WO2005044992A3 (en) Fusion initiation region in rna virus envelope proteins
Ziebuhr et al. Human coronavirus 229E papain-like proteases have overlapping specificities but distinct functions in viral replication
Martínez-Salas et al. Alternative mechanisms to initiate translation in eukaryotic mRNAs
Agol et al. Emergency services of viral RNAs: repair and remodeling
DK1747023T3 (da) Fremgangsmåder og sammensætninger til formindskelse af HCV-virusgenommængder i en målcelle
WO2005014806A3 (en) Conserved hbv and hcv sequences useful for gene silencing
DK1749097T3 (da) Replikationskompetente vira, der er i stand til silencing af ekspression af virushæmmende faktor
WO2007097820A3 (en) Viral gene products and methods for vaccination to prevent viral associated diseases
ATE495253T1 (de) Die replikation des hepatitis-c-virus-replikons hemmendes nukleaseresistentes rna-aptamer
ATE552344T1 (de) Viren mit erhöhter lytischer kraft
Arhab et al. Horizontal gene transfer as a mechanism for the promiscuous acquisition of distinct classes of IRES by avian caliciviruses
EP2527445A3 (en) Treatment and prevention of influenza
Kokkonos et al. Evolutionary selection of pestivirus variants with altered or no microRNA dependency
WO2011133040A3 (en) Replication-competent adenoviruses
ATE507293T1 (de) Zum gen-silencing geeignete konservierte hbv- und hcv-sequenzen
Sultana et al. Insights into the roles of histone chaperones in nucleosome assembly and disassembly in virus infection
WO2010107742A3 (en) Methods and compositions of treating a flaviviridae family viral infection